Latest Sales Guidance News

Mount Gibson Iron suspends mining at Koolan Island following a significant rockfall, withdrawing FY26 sales guidance and initiating workforce reductions while advancing rehabilitation efforts.

Adairs Limited has updated its first half FY26 sales and gross margin guidance, reflecting moderated growth and mixed brand performances as it prepares for a critical peak trading period.

Iluka Resources has withdrawn its synthetic rutile sales guidance due to uncertainties stemming from Venator's sale and idling of its Greatham titanium dioxide facility. The move highlights growing market challenges and contract renegotiations in the pigment sector.

Santos Limited reported robust Q3 2025 results, highlighted by the Barossa LNG project commencing production and Pikka phase 1 nearing first oil. The company’s diversified portfolio and operational discipline underpin a confident outlook despite some operational delays.

Sheffield Resources achieved a record quarterly concentrate production at its Thunderbird mine but faces subdued zircon sales due to challenging market conditions in China, withholding December quarter guidance.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.

US Masters Residential Property Group reports a half-year profit and advances its ambitious asset sales program, while navigating a significant US tax structure change and mixed market conditions.

Whitehaven Coal reported a robust FY25 with underlying NPAT of $319 million and record production, while maintaining a strong balance sheet and announcing shareholder returns. The company’s FY26 guidance signals continued operational focus amid stabilizing coal markets.

Mount Gibson Iron reported a significant net loss for FY25 amid weaker iron ore prices but is pivoting towards gold with a major acquisition in the Northern Territory.

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.